Interview with Dr. Vanessa Schmidt-Kruger
Hearing # 37 of German Corona Extra-Parliamentary Inquiry Committee
30 January, 2021
===============
VSK: I’m a cell biologist and my specialist field is the functional characterisation and elucidation of proteins, i.e., I understand how proteins are produced, how they are transported in the cell, how they are taken up by cells, how they are metabolised, how intra- and intercellular communication takes place, including within tissue, and how organs interact. This is all very important if one wishes to conduct a risk assessment: how the vaccine functions for example, and the dangers/risks of the lipid nanoparticles (LNPs). This technology is not really new: it’s novel as a vaccine, but we have been using these LNPs in research for over 20 years, and we have always been struggling with the problem of toxicity of the lipids and balancing this against their efficacy.
The first point is that the BioNTech vaccine that is currently already being used is not highly purified, it contains contaminants of certain components. This is in the EMA’s Open Assessment Report, the Agency that has granted the authorisation to this vaccine. The EMA has written this report, and covers this point.
Secondly, I would like to go into the first clinical study of the BioNTech vaccine, and how the quantity of vaccine to be used was determined: this has not been correctly characterised from a scientific perspective in my opinion.
Point 3 relates to the effects or risks of the LNPs, and again I will be focusing on the BioNTech vaccine, the preclinical study they conducted, everything that came out in that, and what has not been discussed in public, and also what the publications say. This is basically not the only research study [on this].
And finally if we have time I would like to talk about the long-term consequences relating to immune disease, that is an aspect that has not yet been discussed in public at all
The problem that BioNTech had is that in the clinical phase the product, i.e. the RNA, was produced with completely different techniques to how it is being produced now. During the clinical phase they only needed small volumes of vaccine, they were able to use very expensive techniques that delivered highly purified end products. Now that they have entered mass production, that is no longer possible, they have had to switch to lower-cost processes.
There are also contaminants with regard to the lipids.... And they have to do all this by the end of July 2021. So they don’t know the source of the contaminants, and the EMA Committee didn’t go into what consequences the contamination might have.
http://enformtk.u-aizu.ac.jp/howard/gcep_dr_vanessa_schmidt_krueger/?fbclid=IwAR1we4j8kJ3fwyLajLkvvqsx2KVKtBp82Y44Y8QtOU70qYbQ_ZsylPYDDNk